Published in Hepatitis Weekly, April 7th, 2003
That is what happened to children enrolled in a prospective open trial to treat chronic hepatitis B infections with lamivudine, according to Corina Hartman and colleagues at Meyer Children's Hospital of Haifa in Haifa, Israel.
Each of the 20 children, aged 8.5 to 19 years, had previously received interferon, a standard therapy for chronic hepatitis B, and none had responded to that treatment.
"At the end of 1 year, HBV...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.